<DOC>
	<DOCNO>NCT01791361</DOCNO>
	<brief_summary>This non-interventional retrospective medical record review study assess prevalence KRAS test impact KRAS test result pattern Vectibix use patient metastatic colorectal cancer ( mCRC ) treat Vectibix select European country 3 round . As optimal use Vectibix also require accurate KRAS mutation testing , study also assess data laboratory perform KRAS test . The study also monitor change pattern Vectibix treatment different round study .</brief_summary>
	<brief_title>Medical Records Review Describe Patterns KRAS Testing Vectibix Use Europe</brief_title>
	<detailed_description>The medical record review conduct 3 round month 0 , 12 , 24 first medical record abstraction . Before begin study , sample list create Amgen merge list oncologist ( contact information ) collect Cegedim , ESMO , major cancer center oncology clinic various country within Europe . In round medical record review , potential participating oncologist randomly sample identified oncologist . Potential oncologist contact letter , telephone email . The oncologist introduce study , eligibility participate study assess use standardized questionnaire . The number oncologists sample per country proportional number oncology center per country . Approximately 50 oncologist participate round study . From eligible participate oncologist , study staff obtain approximately 3 medical record patient receive Vectibix treatment mCRC 6-month period prior time contact relevant oncologist involve experimental clinical trial treat Vectibix . A write consent may obtain participate patient access medical record , depend local law . Medical information abstract medical record use standardized form . Such medical information include occurrence timing treatment Vectibix oxaliplatin-containing chemotherapy , diagnosis mCRC occurrence , time result KRAS test . The oncologist also ask collect information pathology laboratory perform KRAS mutation test patient , use standardized pathology data extraction form .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Physician Must practice oncology specialist Must treat least 5 new continue patient metastatic colorectal cancer per quarter Must prescribe Vectibix treat least 5 new continue patient metastatic colorectal cancer past 6 month Physician Must oncologist sample medical centre round study Must take part study previously Patient Inclusion Criteria Must receive Vectibix treatment metastatic colorectal cancer 6month period prior time medical record obtain Must experimental clinical trial time receive Vectibix Must provide write consent allow access medical record ( local law require ) Must take part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>